PeptiDream, a public Tokyo-based biopharmaceutical company, has announced a multi-target discovery and optimization collaboration with Sanofi. PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi. Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.
PeptiDream will receive an undisclosed upfront payment, research funding and will be eligible for payments associated with the achievement of certain preclinical and clinical development milestones. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.
In the past five years, PeptiDream has established funded discovery collaborations with Amgen, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo and Merck, as well as a strategic collaboration with Ipsen, all of which are actively progressing identified hits toward the clinic. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb and Novartis.